Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 106 Results

Title
Intervention Indication Therapeutic Area Year Actions
Plinabulin in addition to docetaxel for advanced, metastatic non-small-cell lung cancer - second line or greater Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Plinabulin (BPI-2358) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Pralsetinib for RET-fusion positive metastatic non-small-cell lung cancer Pralsetinib (BLU-667; Gavreto) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Ramucirumab in addition to erlotinib for EGFR mutation-positive metastatic non-small-cell lung cancer Erlotinib (Tarceva; erlotinib hydrochloride) , Ramucirumab (Cyramza) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2019 View  |  Download
Repotrectinib for treating advanced or metastatic nonsmall-cell lung cancer with ROS1-postive mutation Repotrectinib (TPX 0005) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer Endocrine therapy , Ribociclib (Kisqali; LEE-011; ribociclib succinate) Breast cancer , Non-small-cell lung cancer (NSCLC) Breast Cancer , Lung and Respiratory Cancer 2024 View  |  Download
Rovalpituzumab tesirine for the treatment of relapsed or refractory small cell lung cancer Rovalpituzumab tesirine (SC16LD6.5; Rova-T) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2017 View  |  Download
Sacituzumab govitecan for previously treated advanced non-small cell lung cancer Sacituzumab Govitecan (IMMU-132; Trodelvy) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Selpercatinib for metastatic RET fusion-positive non-small cell lung cancer Selpercatinib (LOXO-292; LY3527723) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2019 View  |  Download
Selpercatinib for previously untreated advanced RET fusion-positive non-small cell lung cancer Selpercatinib (LOXO-292; LY3527723) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Selpercatinib for treating advanced solid tumours with RET gene fusion in people aged 12 years and older Selpercatinib (LOXO-292; LY3527723) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications